{"id":63911,"date":"2026-04-24T20:59:56","date_gmt":"2026-04-24T12:59:56","guid":{"rendered":"https:\/\/flcube.com\/?p=63911"},"modified":"2026-04-24T20:59:57","modified_gmt":"2026-04-24T12:59:57","slug":"abbvie-receives-fda-complete-response-letter-for-trenibote-with-manufacturing-clarifications-requested","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63911","title":{"rendered":"AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested"},"content":{"rendered":"\n<p><strong>AbbVie Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) disclosed on April 23, 2026, that it has received a <strong>Complete Response Letter (CRL)<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> regarding its <strong>Biologics License Application (BLA)<\/strong> for <strong>trenibotulinumtoxinE (TrenibotE)<\/strong>. The regulatory feedback requests additional information about manufacturing processes but notably identifies no safety or efficacy concerns and does not require additional clinical studies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-status-update\">Regulatory Status Update<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>AbbVie Inc. (NYSE: ABBV)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>TrenibotulinumtoxinE (TrenibotE)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Biologics License Application (BLA)<\/td><\/tr><tr><td><strong>FDA Action<\/strong><\/td><td>Complete Response Letter (CRL)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>April 23, 2026<\/td><\/tr><tr><td><strong>Primary Request<\/strong><\/td><td>Additional manufacturing process information<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-clinical-data\">Product Profile &amp; Clinical Data<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-therapeutic-differentiation\">Therapeutic Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Classification<\/strong>: First-in-class botulinum neurotoxin serotype E<\/li>\n\n\n\n<li><strong>Onset of Action<\/strong>: Rapid onset as early as <strong>8 hours<\/strong> after administration (earliest assessment time)<\/li>\n\n\n\n<li><strong>Duration of Effect<\/strong>: Short duration of <strong>2-3 weeks<\/strong><\/li>\n\n\n\n<li><strong>Target Indication<\/strong>: Moderate to severe glabellar lines<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-evidence-base\">Clinical Evidence Base<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population<\/strong>: Over <strong>2,100 patients<\/strong> treated in clinical program<\/li>\n\n\n\n<li><strong>Pivotal Studies<\/strong>: Two Phase 3 clinical trials for glabellar lines treatment<\/li>\n\n\n\n<li><strong>Safety Assessment<\/strong>: Phase 3 open-label safety study<\/li>\n\n\n\n<li><strong>Regulatory Feedback<\/strong>: No safety or efficacy concerns identified by FDA<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-response-amp-timeline\">Strategic Response &amp; Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Company Confidence<\/strong>: AbbVie expressed confidence in addressing FDA comments promptly<\/li>\n\n\n\n<li><strong>Response Timeline<\/strong>: Thorough response expected to be submitted in coming months<\/li>\n\n\n\n<li><strong>No Additional Studies<\/strong>: FDA did not request supplementary clinical trials<\/li>\n\n\n\n<li><strong>Manufacturing Focus<\/strong>: Clarifications limited to process documentation and validation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<p>The CRL represents a manageable regulatory hurdle rather than a fundamental safety or efficacy concern. TrenibotE&#8217;s unique profile\u2014featuring rapid onset and short duration\u2014differentiates it from existing botulinum toxin products in the aesthetic market, potentially appealing to patients seeking temporary cosmetic effects or those new to neuromodulator treatments.<\/p>\n\n\n\n<p>AbbVie&#8217;s established expertise in navigating complex regulatory pathways, particularly with its successful Botox franchise, positions the company well to efficiently resolve the manufacturing information requests and advance toward potential approval.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding AbbVie&#8217;s regulatory interactions, product development timeline, and market positioning. Actual approval timelines and commercial outcomes may differ based on FDA review processes, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie Inc. (NYSE: ABBV) disclosed on April 23, 2026, that it has received a Complete&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[234,853],"class_list":["post-63911","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abbvie","tag-nyse-abbv"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie Inc. (NYSE: ABBV) disclosed on April 23, 2026, that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE). The regulatory feedback requests additional information about manufacturing processes but notably identifies no safety or efficacy concerns and does not require additional clinical studies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63911\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested\" \/>\n<meta property=\"og:description\" content=\"AbbVie Inc. (NYSE: ABBV) disclosed on April 23, 2026, that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE). The regulatory feedback requests additional information about manufacturing processes but notably identifies no safety or efficacy concerns and does not require additional clinical studies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63911\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-24T12:59:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-24T12:59:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63911#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63911\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested\",\"datePublished\":\"2026-04-24T12:59:56+00:00\",\"dateModified\":\"2026-04-24T12:59:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63911\"},\"wordCount\":352,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AbbVie\",\"NYSE: ABBV\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63911#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63911\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63911\",\"name\":\"AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-24T12:59:56+00:00\",\"dateModified\":\"2026-04-24T12:59:57+00:00\",\"description\":\"AbbVie Inc. (NYSE: ABBV) disclosed on April 23, 2026, that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE). The regulatory feedback requests additional information about manufacturing processes but notably identifies no safety or efficacy concerns and does not require additional clinical studies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63911#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63911\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63911#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested - Insight, China&#039;s Pharmaceutical Industry","description":"AbbVie Inc. (NYSE: ABBV) disclosed on April 23, 2026, that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE). The regulatory feedback requests additional information about manufacturing processes but notably identifies no safety or efficacy concerns and does not require additional clinical studies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63911","og_locale":"en_US","og_type":"article","og_title":"AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested","og_description":"AbbVie Inc. (NYSE: ABBV) disclosed on April 23, 2026, that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE). The regulatory feedback requests additional information about manufacturing processes but notably identifies no safety or efficacy concerns and does not require additional clinical studies.","og_url":"https:\/\/flcube.com\/?p=63911","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-24T12:59:56+00:00","article_modified_time":"2026-04-24T12:59:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63911#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63911"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested","datePublished":"2026-04-24T12:59:56+00:00","dateModified":"2026-04-24T12:59:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63911"},"wordCount":352,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AbbVie","NYSE: ABBV"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63911#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63911","url":"https:\/\/flcube.com\/?p=63911","name":"AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-24T12:59:56+00:00","dateModified":"2026-04-24T12:59:57+00:00","description":"AbbVie Inc. (NYSE: ABBV) disclosed on April 23, 2026, that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE). The regulatory feedback requests additional information about manufacturing processes but notably identifies no safety or efficacy concerns and does not require additional clinical studies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63911#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63911"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63911#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63911"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63911\/revisions"}],"predecessor-version":[{"id":63914,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63911\/revisions\/63914"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}